EcoDrugPlus

Eph Receptor A3

Ensembl ID : ENSOTSG00005011210
Gene Symbol: EPHA3
1 Cross references
206 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSOTSG00005010264
Gene Symbol: EPHA3
1 Cross references
206 Possible Orthologues:

F2r Like Thrombin Or Trypsin Receptor 3

Ensembl ID : ENSOTSG00005045648
Gene Symbol: F2RL3
1 Cross references
189 Possible Orthologues:

F2r Like Thrombin Or Trypsin Receptor 3

Ensembl ID : ENSOTSG00005044582
Gene Symbol: F2RL3
1 Cross references
189 Possible Orthologues:

Fau Ubiquitin Like And Ribosomal Protein S30 Fusion A

Ensembl ID : ENSOTSG00005035746
Gene Symbol: FAUA
1 Cross references
295 Possible Orthologues:

Fau Ubiquitin Like And Ribosomal Protein S30 Fusion B

Ensembl ID : ENSOTSG00005007540
Gene Symbol: FAUB
1 Cross references
20 Possible Orthologues:

Fyn Proto-Oncogene, Src Family Tyrosine Kinase B

Ensembl ID : ENSOTSG00005018238
Gene Symbol: FYNB
1 Cross references
190 Possible Orthologues:

Fyn Proto-Oncogene, Src Family Tyrosine Kinase B

Ensembl ID : ENSOTSG00005016411
Gene Symbol: FYNB
1 Cross references
194 Possible Orthologues:

G Protein-Coupled Receptor 119

Ensembl ID : ENSOTSG00005036245
Gene Symbol: GPR119
1 Cross references
174 Possible Orthologues:

G1/s-Specific Cyclin-D1

Ensembl ID : ENSOTSG00005016695
Gene Symbol: LOC112263573
3 Cross references
229 Possible Orthologues:

G1/s-Specific Cyclin-D1-Like

Ensembl ID : ENSOTSG00005028290
Gene Symbol: LOC112249039
3 Cross references
228 Possible Orthologues:

Gtpase Kras

Ensembl ID : ENSOTSG00005016635
Gene Symbol: LOC112252543
3 Cross references
197 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).